July 25, 2014
Stop by and visit us at Booth #310 throughout the week!
To schedule a meeting with us while we're here, please click here.
CTI's collaborations on two landmark studies will be presented as part of the Congress:
"FINAL LONG-TERM ASSESSMENT OF GRAFT FUNCTION IN PATIENTS COMPLETING THE SPARE-THE-NEPHRON (STN) STUDY WITH A FUNCTIONING GRAFT"
MR WEIR, R KALIL, RD GORDON, L ANANDAGODA, S LINDSEY AND THE STN EXTENSION STUDY INVESTIGATORS
Poster Session I
Sunday, July 27, 2014
6:30 pm - 8:00 pm
"TREATMENT WITH QPI-1002, A SHORT INTERFERING (SI) RNA FOR THE PROPHYLAXIS OF DELAYED GRAFT FUNCTION"
VR Peddi, LE Ratner, M Cooper, OA Gaber, S Feng, P Tso, V Bowers, R Naraghi, K Budde, M Polinsky, EC Squiers, SS Erlich and for the QPI-1002 DGF Study Investigators Group.
11:27am on Monday, July 28, 2014
as a part of "11:15am-12:45pm Late Breaking Abstract"
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.